Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
sabato, settembre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Oruka Therapeutics Inc
ORKA
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$84.46
-1.03
-1.2%
In chiusura: Sep 25, 5:00 PM EST
$86.00
1.54
1.82%
Post-mercato: 9:27 AM EST
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Dividendi
Confronta
Opzioni
Rapporto azionario
Oruka Therapeutics Financials
Oruka Therapeutics (ORKA) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Oruka Therapeutics Q2 EPS $(0.55) Misses $(0.51) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.51) by 7.84 percent. This is a 19.57 percent decrease over losses of $(0.46) per share
Benzinga Newsdesk
PRO
Oruka Therapeutics Q1 EPS $(0.48) Beats $(0.55) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.55) by 12.73 percent. This is a 20 percent decrease over losses of $(0.40) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q4 EPS $(0.45) Beats $(0.64) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(0.64) by 29.47 percent. This is a 8.16 percent increase over losses of $(0.49) per share from
Benzinga Newsdesk
PRO
Oruka Therapeutics Q3 EPS $(0.55) Beats $(0.59) Estimate
Oruka Therapeutics (NASDAQ:ORKA) reported quarterly losses of $(0.55) per share which beat the analyst consensus estimate of $(0.59) by 6.14 percent. This is a 62.33 percent increase over losses of $(1.46) per share from
Benzinga Newsdesk
Stock Market Today: Dow Jones, Nasdaq, Futures Gain As Government Enters 2nd Week Of Shutdown—Plug, Lithium Americas, UiPath In Focus (UPDATED)
Editor’s Note: The future prices of benchmark tracking ETFs were updated in the story. U.S. stock futures rose on Monday following Friday’s mixed moves. Futures of major benchmark indices were higher.
Rishabh Mishra
Constellation Brands, Aehr Test Systems And 3 Stocks To Watch Heading Into Monday
US stock futures up, focus on Constellation Brands, SkyWater Tech, Aehr Test Systems, Oruka Therapeutics and VCI Global earnings.
Avi Kapoor
Privacy Manager